FatiguePhase 2NCT05212701
To Assess Efficacy and Safety of Oral Reparixin in Patients With Fatigue and Locally Advanced / Metastatic Breast Cancer
A Phase 2 study testing Reparixin in people with Fatigue and Locally Advanced or Metastatic Breast Cancer, run by Dompé Farmaceutici S.p.A at 20 sites in 3 countries.
Trial summary
Primary objective: To assess the efficacy of reparixin compared to placebo in limiting CRF in adult patients with locally advanced or metastatic breast cancer undergoing single-agent taxane chemotherapy, using FACITFatigue scale. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Fatigue, Locally Advanced or Metastatic Breast Cancer
- What is being tested?
- Reparixin
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- 20 sitesin 3 countries
- Study dates
- 19 Apr 2022to Jul 2024
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Provide written informed consent before the initiation of any study-specific procedures
- 2. Male or female ≥18 years of age
- 3. Pathologically documented locally advanced (not amenable to surgical resection) or metastatic HER2-negative breast cancer
- 4. Candidate to receive cycle 1 of treatment with single-agent taxane-based chemotherapy (paclitaxel, nab-paclitaxel, docetaxel)
- 5. CRF score from 1 to 6 on a numeric rating scale (NRS) from 0 to 10, where 0 = no fatigue, 10 = worst possible fatigue, during the previous 24 hours and lasting for a minimum of 4 days
- 6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2
Show all 17Show fewer
- 7. Life expectancy of at least 6 months as estimated by the investigator
- 8. Able to swallow and retain oral medication (intact tablet)
- 9. Adequate organ function (defined by the following parameters):
- Serum creatinine < 140 μmol/L (< 1.6 mg/dL) or creatinine clearance > 60 mL/min
- Serum hemoglobin ≥ 11 g/dL; absolute neutrophil count ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L.
- Serum bilirubin ≤ upper limit of normal (ULN), except patients with Gilbert's syndrome.
- Serum Alanine aminotransferase (ALT), aspartate transaminase (AST) ≤ 1.5 x ULN
- Alkaline phosphatase ≤ 2.5 x ULN
- prothrombin time (PT) or activated partial thromboplastin time (aPTT, PTT) ≤ULN
- 10. No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus-I and -II positive status
- 11. If a female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) serum pregnancy test and use a highly effective method to avoid pregnancy for the duration of the trial and for at least 6 months after completion of docetaxel, paclitaxel or nab-paclitaxel therapy. Males of reproductive potential should use effective contraception during treatment and for 6 months after the last dose of docetaxel, paclitaxel or nab-paclitaxel
Who cannot join
- 1. More than 1 prior systemic chemotherapy for advanced disease. Patients may have received hormone therapy and biological therapy (e.g. CDK4/6 inhibitors), either alone or in combination
- 2. Malabsorption syndrome or disease significantly affecting gastrointestinal function including but not limited to gastrectomy or gastric outlet obstruction
- 3. History or evidence of neurological or psychiatric disorder or any other concurrent medical condition or disease that, in the opinion of the investigator or Medical Monitor may influence understanding of study and informed consent procedures, would pose a risk to subject safety or would interfere with the study evaluation, procedures or completion
- 4. Positive severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) antigenic test performed through nasal swab
- 5. Treatment with any investigational agent within at least 28 days or 5 half-lives (whatever is shorter) prior to Visit 1, recovered from previous treatment toxicity to Grade1 or better
- 6. Brain metastases that are untreated or symptomatic, or require any radiation, surgery, or continued steroid therapy to control symptoms from brain metastases
Show all 34Show fewer
- 7. Treatment with oral morphine greater than 60 mg a day or equivalent
- 8. Other causes of fatigue, including, but not restricted to:
- untreated hypothyroidism
- pituitary disorder
- insomnia
- alcohol abuse
- uncontrolled pain as defined by pain intensity greater than 3 on a NRS (0-10)
- chronic >G2 anemia
- uncontrolled cardiac disease or cardiovascular disorders
- acute infections
- major depressive disorder
- uncontrolled neurological disorders
- 9. Concomitant use of other medications/dietary supplements for fatigue
- 10. Concomitant use of cannabidiol (CBD) or Tetrahydrocannabinol (THC).
- 11. Any other invasive malignancy from which the patient has been disease-free for less than 5 years with the exception of curatively treated basal or squamous cell skin cancer
- 12. Patients who are committed to an institution by virtue of an order issued either by the judicial or the administrative authorities
- 13. Patients who are employees of the sponsor or investigator or otherwise dependent on them
- 14. History of:
- intolerance or hypersensitivity to paclitaxel, nab-paclitaxel, docetaxel or any other concomitant drug used in the study
- intolerance or hypersensitivity to ibuprofen or to non-steroidal anti-inflammatory drug (NSAIDs)
- intolerance or hypersensitivity to more than one medication belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib; hypersensitivity to sulphanilamide antibiotics alone (e.g. sulfamethoxazole) does not qualify for exclusion
- lactase deficiency, galactosaemia or glucose-galactose malabsorption
- documented allergic reaction or severe reaction of any kind to dairy products
- 15. Pregnancy or lactation or unwillingness to use adequate method of birth control. Effective contraceptive measures include intrauterine device (IUD), bilateral tubal occlusion, vasectomised partner, sexual abstinence.
- 16. Concomitant use of ibuprofen or CYP2C9 inhibitors/inducers and inability to pause these drugs during the study
- 17. Concurrent use of NSAIDs or inability to stop NSAIDs during the treatment period
- 18. Any contraindications to NSAIDs including but not limited to previous experience of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
- 19. A history of gastrointestinal bleeding or perforation related to previous NSAIDs therapy or an active or history of recurrent peptic ulcer/haemorrhage, coagulation disturbances
Trial locations and contacts
20 sites in 3 countries.
20 sites in 3 countries
Italy14 sites
IRCCS Oncologico Istituto Tumori Giovanni Paolo II
Bari, 70124
Azienda Ospedaliero Universitaria di Bologna - Policlinico S. Orsola-Malpighi
Bologna, 40138
ASST-Spedali Civili di Brescia
Brescia, 25123
E.O. Ospedali Galliera
Genova, 16128
Istituto Scientifico Romagnolo per lo Studio e La Cura dei Tumori SRL IRCCS
Meldola (FC), 47014
IRCCS - Istituto Europeo di Oncologia
Milan, 20141
Azienda Ospedaliera di Perugia, Ospedale Santa Maria della Misericordia
Perugia, 06132
Azienda Ospedaliera Universitaria Pisana
Pisa, 56126
"Azienda Unità Sanitaria Locale della Romagna Ospedale Infermi di Rimini"
Rimini, 47923
Istituti Fisioterapici Ospitalieri- IFO - Istituto Regina Elena
Roma, 00144
Fondazione Policlinico Universitario A. Gemelli, IRCCS
Roma, 00168
"Azienda Ospedaliero Universitaria Sant'Andrea "
Roma, 00189
Ospedale Giuseppe Mazzini di Teramo
Teramo, 64100
A.O. "Pia Fondazione Cardinale Panico"
Tricase, 73039
Germany4 sites
Kliniken Essen-Mitte, Klinik für Senologie/ Interdisziplinäres Brustzentrum
Essen, 45136
Praxis für Interdisziplinäre Onkologie & Hämatologie
Freiburg im Breisgau, 79110
Mammazentrum Hamburg am Krankenhaus Jerusalem
Hamburg, 20357
Klinikum Ernst von Bergmann, Frauenklinik
Potsdam, 14467
United States2 sites
Waverly Hematology
Cary, North Carolina, 27518
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203
About this study
Official title: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess Efficacy and Safety of Reparixin in Cancer Related Fatigue in Pts With Advanced / Metastatic Breast Cancer Undergoing Taxane-based Chemotherapy.
Primary objective:
- To assess the efficacy of reparixin compared to placebo in limiting CRF in adult patients with locally advanced or metastatic breast cancer undergoing single-agent taxane chemotherapy, using FACITFatigue scale.
Read more
The secondary objectives are:
- To evaluate change in Quality of Life in the two treatment arms
- To assess the percentage of patients treated with reparixin compared to placebo delaying and discontinuing chemotherapy
- To assess Patient Global Impression of Severity (PGI-S) score and Patient Global Impression of Change (PGI-C) score associated with reparixin compared to placebo
- To assess the effect of reparixin compared to placebo on ECOG PS
- To assess the effects of reparixin vs placebo on Objective Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS)
The safety objective is:
- To assess the safety and tolerability of reparixin in adult patients undergoing taxane-containing chemotherapy.
The pharmacokinetic (PK) objective is:
- To define the PK profile of orally administered reparixin, its metabolites (DF2243Y, DF2188Y, ibuprofen) and concomitant antineoplastic agents (paclitaxel, or nab-paclitaxel or docetaxel) in adult patients with locally advanced or metastatic breast cancer.
Read the detailed description
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled study. It will evenly randomize 68 evaluable men and women adult patients with CRF in locally advanced or metastatic breast cancer who are candidates to start single-agent taxane chemotherapy (paclitaxel, nab-paclitaxel or docetaxel). CRF will be assessed at baseline on a scale from 0 - 10 (with 10 being most severe), enrolling any patient who report a score of 1 - 6. Recruitment will be competitive among the study sites, until the planned number of patients is randomized. Patients will be assigned (1:1) to receive either oral reparixin treatment (1200 mg t.i.d. - treatment group) or masked placebo t.i.d. (control group). Randomization will be stratified by site and according to the type of chemotherapy (paclitaxel vs docetaxel vs nab-paclitaxel). Sparse blood samples will be collected in the whole population for reparixin (and metabolites), docetaxel, nab-paclitaxel, paclitaxel PK analysis. Reparixin or placebo will be administered for 16 weeks or until disease progression, withdrawal of consent or unacceptable toxicity, whichever occurs first. Following the completion of the treatment, or after premature discontinuation during the double-blind phase the patients will be followed up for safety assessments for an additional 30 days after last study therapy administration and will be followed for progressive disease and survival until twelve months after last enrolled subject off treatment, or until trial is terminated for other reasons, whatever occurs first.
Number of Patients Sixty-eight (68) evaluable adult patients with CRF with locally advanced or metastatic breast cancer who are candidates to receive single-agent taxane chemotherapy will be included in the study. Assuming that 10% of subjects will not be evaluable for primary analysis, a total of approximately 76 subjects is expected to be enrolled.
- Being tested
- Reparixin, Placebo
- Keywords
- metastatic breast cancer
- Medical subject headings
- Fatigue, Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ReparixinDrug
The oral tablets of the investigational product (IP) will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack (it is preferable that reparixin is taken with food).
PlaceboDrug
The oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack
| Study group | Role | What they receive |
|---|---|---|
| Reparixin | Experimental | Reparixin will be administered orally at the dose of 1200 mg (2 x 600 mg tablets) three times daily (total dose of 3600 mg/day) with no interruptions during each cycle. Receives: Drug: Reparixin |
| Placebo | Placebo comparator | Masked placebo will be administered orally (2 tablets) three times daily with no interruptions during each cycle. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from baseline in FACIT-F score
The Functional Assessment of Chronic Illness Therapy - fatigue (FACIT-fatigue) scale is a 13-item instrument designed to assess fatigue/ tiredness and its impact on daily activities and functioning in a number of chronic diseases. The instrument includes items such as tiredness, weakness, listlessness, lack of energy, and the impact of these feelings on daily functioning (e.g., sleeping, and social activities).
The FACIT-fatigue scale is a 13-item patient-reported measure of fatigue where items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher scores represent better functioning or less fatigue.
Measured: week 16
Secondary outcomes (10)
Change from baseline in FACIT-F score
The Functional Assessment of Chronic Illness Therapy - fatigue (FACIT-fatigue) scale is a 13-item instrument designed to assess fatigue/ tiredness and its impact on daily activities and functioning in a number of chronic diseases. The instrument includes items such as tiredness, weakness, listlessness, lack of energy, and the impact of these feelings on daily functioning (e.g., sleeping, and social activities).
The FACIT-fatigue scale is a 13-item patient-reported measure of fatigue where items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher scores represent better functioning or less fatigue.
Measured: weeks 4, 8 and 12
EQ-5D-5L score
The EQ-5D-5L consists of 2 pages: the EQ-5D-5L descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box of the most appropriate statement in each of the 5 dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state.The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS is used as a quantitative measure of health outcome that reflect the patient's own judgment.
Measured: day 1 of each 21- or 28-day cycle, off treatment visit (or withdrawal), which means up to 70 weeks
Patient Global Impression of Severity (PGI-S) score
The PGI-S is designed to capture subject's perception of overall symptom severity at the time of completion on a 5-point categorical response scale: "Please choose the response below that best describes the severity of your fatigue over the past week" and is scored from 1 to 5, with 1 indicating "None", 2 "Mild", 3 "Moderate", 4 "Severe", 5 "Very Severe". The higher the score, the worse the outcome.
Measured: day 1 of each 21- or 28-day cycle, off treatment visit (or withdrawal) which means up to 70 weeks
Patient Global Impression of Change (PGI-C) score
The PGI-C is designed to capture the subject's perception of change in their overall symptom severity from baseline until the time of completion. Change in severity is captured using a 5- point scale: "Please choose the response below that best describes the overall change in your fatigue since you started receiving the taxane-based chemotherapy" and is scored from 1 to 5, with 1 indicating "Much better", 2 "A little better", 3 "No change", 4 "A little worse", 5 "Much worse". The higher the score, the worse the outcome.
Measured: day 1 of each 21- or 28-day cycle except for cycle 1, off treatment visit (or withdrawal), which means up to 70 weeks
Proportion of patients delaying next administration of chemotherapy due to CRF
Proportion of patients delaying next dosing of chemotherapy due to chronic renal failure (CRF)
Measured: throughout the study, up to 70 weeks
Proportion of patients discontinuing chemotherapy due to CRF
Proportion of patients discontinuing chemotherapy due to chronic renal failure (CRF)
Measured: throughout the study, up to 70 weeks
Change in Eastern Cooperative Oncology Group Performance Status (ECOG PS)
ECOG PS is graded as follow:
0 Fully active, able to carry on all pre-disease performance without restriction
- Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work
- Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours
- Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours
- Completely disabled; cannot carry on any selfcare; totally confined to bed or chair
- Dead The higher the score, the worse the outcome.
Measured: baseline, day 1 of each 21- or 28-day chemotherapy cycle, off treatment visit (or withdrawal) which means up to 70 weeks
Overall Response Rate (ORR)
ORR is defined as the proportion of patients with best overall response of CR or PR according to RECIST 1.1.
Measured: Through study treatment, up to 70 weeks
Progression Free Survival (PFS)
PFS is defined as the time from the date of randomization until the date of the first documented progression or death due to any cause. PFS will be assessed based on local investigator assessment per RECIST 1.1.
Measured: Up to 12 months post-treatment
Overall Survival (OS)
OS is defined as the time from date of first administration of study treatment until date of death due to any cause
Measured: Up to 12 months post-reparixin discontinuation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jan 2022
- Study start19 Apr 2022
- Primary completionJun 2023 (estimated)
- Study completionJul 2024 (estimated)
Why it stopped: Dompé decided to withdraw the study due to the numerous difficulties encountered in enrollment, mainly due to the rapidly and continuously changing oncology drug scenario . No patients were enrolled.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for FatigueStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Enrico Minnella, MD, Study director, Dompé Farmaceutici S.p.A
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05212701
- Sponsor's protocol ID
- REP0121
- Other IDs
- 2021-000382-32
- Status last verified
- Apr 2024
- First submitted
- 29 Dec 2021
- Last updated
- 30 Apr 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2 Study to Assess Efficacy and Safety of Reparixin in Cancer Related Fatigue in Pts With Advanced / Metastatic Breast Cancer Undergoing Taxane-based Chemotherapy.
- ClinicalTrials.gov ID
- NCT05212701
- Acronym / sponsor ID
- REP0121
- Keywords
- metastatic breast cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Dompé decided to withdraw the study due to the numerous difficulties encountered in enrollment, mainly due to the rapidly and continuously changing oncology drug scenario . No patients were enrolled.
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Dompé Farmaceutici S.p.AIndustry (pharma, biotech, devices)
- Study start
- 19 Apr 2022 (actual)
- Primary completion
- Jun 2023 (estimated)
- Study completion
- Jul 2024 (estimated)
- First posted
- 28 Jan 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Primary objective:
- To assess the efficacy of reparixin compared to placebo in limiting CRF in adult patients with locally advanced or metastatic breast cancer undergoing single-agent taxane chemotherapy, using FACITFatigue scale.
The secondary objectives are:
- To evaluate change in Quality of Life in the two treatment arms
- To assess the percentage of patients treated with reparixin compared to placebo delaying and discontinuing chemotherapy
- To assess Patient Global Impression of Severity (PGI-S) score and Patient Global Impression of Change (PGI-C) score associated with reparixin compared to placebo
- To assess the effect of reparixin compared to placebo on ECOG PS
- To assess the effects of reparixin vs placebo on Objective Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS)
The safety objective is:
- To assess the safety and tolerability of reparixin in adult patients undergoing taxane-containing chemotherapy.
The pharmacokinetic (PK) objective is:
- To define the PK profile of orally administered reparixin, its metabolites (DF2243Y, DF2188Y, ibuprofen) and concomitant antineoplastic agents (paclitaxel, or nab-paclitaxel or docetaxel) in adult patients with locally advanced or metastatic breast cancer.
Detailed description
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled study. It will evenly randomize 68 evaluable men and women adult patients with CRF in locally advanced or metastatic breast cancer who are candidates to start single-agent taxane chemotherapy (paclitaxel, nab-paclitaxel or docetaxel). CRF will be assessed at baseline on a scale from 0 - 10 (with 10 being most severe), enrolling any patient who report a score of 1 - 6. Recruitment will be competitive among the study sites, until the planned number of patients is randomized. Patients will be assigned (1:1) to receive either oral reparixin treatment (1200 mg t.i.d. - treatment group) or masked placebo t.i.d. (control group). Randomization will be stratified by site and according to the type of chemotherapy (paclitaxel vs docetaxel vs nab-paclitaxel). Sparse blood samples will be collected in the whole population for reparixin (and metabolites), docetaxel, nab-paclitaxel, paclitaxel PK analysis. Reparixin or placebo will be administered for 16 weeks or until disease progression, withdrawal of consent or unacceptable toxicity, whichever occurs first. Following the completion of the treatment, or after premature discontinuation during the double-blind phase the patients will be followed up for safety assessments for an additional 30 days after last study therapy administration and will be followed for progressive disease and survival until twelve months after last enrolled subject off treatment, or until trial is terminated for other reasons, whatever occurs first.
Number of Patients Sixty-eight (68) evaluable adult patients with CRF with locally advanced or metastatic breast cancer who are candidates to receive single-agent taxane chemotherapy will be included in the study. Assuming that 10% of subjects will not be evaluable for primary analysis, a total of approximately 76 subjects is expected to be enrolled.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Reparixin | Experimental | Drug: ReparixinReparixin will be administered orally at the dose of 1200 mg (2 x 600 mg tablets) three times daily (total dose of 3600 mg/day) with no interruptions during each cycle. |
| Placebo | Placebo comparator | Drug: PlaceboMasked placebo will be administered orally (2 tablets) three times daily with no interruptions during each cycle. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (17 listed)
- 1. Provide written informed consent before the initiation of any study-specific procedures
- 2. Male or female ≥18 years of age
- 3. Pathologically documented locally advanced (not amenable to surgical resection) or metastatic HER2-negative breast cancer
- 4. Candidate to receive cycle 1 of treatment with single-agent taxane-based chemotherapy (paclitaxel, nab-paclitaxel, docetaxel)
- 5. CRF score from 1 to 6 on a numeric rating scale (NRS) from 0 to 10, where 0 = no fatigue, 10 = worst possible fatigue, during the previous 24 hours and lasting for a minimum of 4 days
Key exclusion criteria (34 listed)
- 1. More than 1 prior systemic chemotherapy for advanced disease. Patients may have received hormone therapy and biological therapy (e.g. CDK4/6 inhibitors), either alone or in combination
- 2. Malabsorption syndrome or disease significantly affecting gastrointestinal function including but not limited to gastrectomy or gastric outlet obstruction
- 3. History or evidence of neurological or psychiatric disorder or any other concurrent medical condition or disease that, in the opinion of the investigator or Medical Monitor may influence understanding of study and informed consent procedures, would pose a risk to subject safety or would interfere with the study evaluation, procedures or completion
- 4. Positive severe acute respiratory syndrome coronavirus 2 (SARSCoV- 2) antigenic test performed through nasal swab
- 5. Treatment with any investigational agent within at least 28 days or 5 half-lives (whatever is shorter) prior to Visit 1, recovered from previous treatment toxicity to Grade1 or better
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ReparixinThe oral tablets of the investigational product (IP) will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack (it is preferable that reparixin is taken with food). | Drug | Reparixin |
| PlaceboThe oral tablets of masked placebo will be administered with water prior to the start of the anticancer treatment infusion on Day 1 Cycle 1 and then administered approximately every eight hours (± 2 h) with a glass of water (about 250 mL) and a light meal or snack | Drug | Placebo |
Primary outcome
Change from baseline in FACIT-F score
Time frame: week 16
The Functional Assessment of Chronic Illness Therapy - fatigue (FACIT-fatigue) scale is a 13-item instrument designed to assess fatigue/ tiredness and its impact on daily activities and functioning in a number of chronic diseases. The instrument includes items such as tiredness, weakness, listlessness, lack of energy, and the impact of these feelings on daily functioning (e.g., sleeping, and social activities). The FACIT-fatigue scale is a 13-item patient-reported measure of fatigue where items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52, where higher scores represent better functioning or less fatigue.
10 secondary outcomes
Change from baseline in FACIT-F score
Time frame: weeks 4, 8 and 12
EQ-5D-5L score
Time frame: day 1 of each 21- or 28-day cycle, off treatment visit (or withdrawal), which means up to 70 weeks
Patient Global Impression of Severity (PGI-S) score
Time frame: day 1 of each 21- or 28-day cycle, off treatment visit (or withdrawal) which means up to 70 weeks
Patient Global Impression of Change (PGI-C) score
Time frame: day 1 of each 21- or 28-day cycle except for cycle 1, off treatment visit (or withdrawal), which means up to 70 weeks
Proportion of patients delaying next administration of chemotherapy due to CRF
Time frame: throughout the study, up to 70 weeks
Proportion of patients discontinuing chemotherapy due to CRF
Time frame: throughout the study, up to 70 weeks
Change in Eastern Cooperative Oncology Group Performance Status (ECOG PS)
Time frame: baseline, day 1 of each 21- or 28-day chemotherapy cycle, off treatment visit (or withdrawal) which means up to 70 weeks
Overall Response Rate (ORR)
Time frame: Through study treatment, up to 70 weeks
Progression Free Survival (PFS)
Time frame: Up to 12 months post-treatment
Overall Survival (OS)
Time frame: Up to 12 months post-reparixin discontinuation
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2024.
Related trials for Fatigue
Enrolling by invitation
Dance-Based Exercise for Cancer-Related Fatigue in Breast Cancer Patients
Breast Neoplasms
Not yet recruiting
Mind Body Reprogramming Therapy for Adolescents With Chronic Fatigue
Chronic Fatigue
Not yet recruiting
Comparison of Functional Inspiratory Muscle Training and Combined Exercise Training in Individuals With Type 2 Diabetes
Type 2 Diabetes Mellitus
Recruiting
Acute Effects of Post-Exercise Hyperoxia on Recovery in Cycling
Athletic Performance, Hyperbaric Oxygenation
Recruiting
Recovery After Fatigue in Young Athletes: Comparison Between TECAR Therapy and Cycle Ergometer"
Muscle Fatigue, Healthy Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Enrico Minnella, MD study director
Dompé Farmaceutici S.p.A
20 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Reparixin in people with Fatigue and Locally Advanced or Metastatic Breast Cancer, run by Dompé Farmaceutici S.p.A at 20 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 17 inclusion and 34 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 30 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in Italy, Germany, United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from baseline in FACIT-F score (time frame: week 16). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2024.